Open AccessJournal Article
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.
Creaven Pj,Allen Lm,Muggia Fm +2 more
About:
This article is published in Cancer chemotherapy reports.The article was published on 1972-10-01 and is currently open access. It has received 68 citations till now. The article focuses on the topics: Camptothecin & Toxicity.read more
Citations
More filters
Journal ArticleDOI
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Noriyuki Masuda,Masahiro Fukuoka,Yoko Kusunoki,Kaoru Matsui,Nobuhide Takifuji,Shinzoh Kudoh,Shunichi Negoro,Masayuki Nishioka,Kazuhiko Nakagawa,Minoru Takada +9 more
TL;DR: CPT-11 is an active agent against refractory or relapsed SCLC and deserves to be studied more closely as both a single agent and in combination with other drugs to treat patients with SclC.
Journal ArticleDOI
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Masahiro Fukuoka,Hisanobu Niitani,Akira Suzuki,M Motomiya,K Hasegawa,Yutaka Nishiwaki,Takayuki Kuriyama,Yutaka Ariyoshi,S. Negoro,Noriyuki Masuda +9 more
TL;DR: CPT-11 is a very active agent for NSCLC with acceptable toxicities and further trials in combination with other agents for this disease are warranted.
Journal ArticleDOI
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Eric K. Rowinsky,Louise B. Grochow,Carolyn B. Hendricks,David S. Ettinger,Arlene A. Forastiere,L A Hurowitz,William P. McGuire,S E Sartorius,B G Lubejko,Scott H. Kaufmann +9 more
TL;DR: Neutropenia is the dose-limiting toxicity, and 1.5 mg/m2 is the recommended starting dose of topotecan for both minimally and heavily pretreated patients in future phase II trials, with escalation to 2.0 mg/ m2 if treatment is well tolerated.
Journal ArticleDOI
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
TL;DR: The MTD of CPT-11 administered as a 30-minute IV infusion every 3 weeks is 600 mg/m2, with granulocytopenia being dose-limiting, and the activity of this agent in 5-FU-refractory colorectal carcinoma makes it unique and mandates expedited phase II testing.
Journal ArticleDOI
Topoisomerase I inhibitors: topotecan and irenotecan.
Related Papers (5)
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin
Yaw Huei Hsiang,Leroy F. Liu +1 more